<unk>  should be avoided in individuals with a history of or known susceptibility to arterial or venous thrombosis (blood clots), due to an increased risk of cardiovascular problems such as venous thromboembolism (VTE), myocardial infarction, and ischemic stroke. This includes women with: * History of deep vein thrombosis (DVT) or pulmonary embolism (PE) not receiving anticoagulants * Acute DVT/PE * Prolonged immobilization due to major surgery * Advanced diabetes mellitus with vascular disease * Migraine with aura * Hypertension ≥160/100 * Vascular disease * Current and history of ischemic heart disease * Multiple risk factors for atherosclerotic cardiovascular disease (e.g. older age, smoking, diabetes, hypertension, low HDL, high LDL, or high triglyceride levels) * Age ≥35 and smoking ≥15 cigarettes/day * History of cerebrovascular accident * Systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies * Complicated valvular heart disease Except when being used to treat it,<unk>  should be avoided in women with current breast cancer due to a possible worsening of prognosis.<unk>  should also be avoided in breastfeeding women who are less than 21 days postpartum due to an increased risk of VTE.<unk>  use in breastfeeding women who are at least 21 days postpartum should be discussed with a provider and include information on the advantages, disadvantages, and alternatives for using<unk> . Due to risk of cholestatic hepatotoxicity, it is widely considered that COCs containing<unk>  should be avoided in women with a history of cholestasis of pregnancy, hepatic tumors, active hepatitis, and familial defects in biliary excretion.
Ethinylestradiol
Vinyltestosterone
Haloprogesterone
Ethyltestosterone
Progestogen
Progestogen 
Methylestradiol
Cloxestradiol acetate